Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.

被引：0
|
作者：
Anandappa, G.
Sala, E.
Cheow, H. K.
Bird, N. J.
Shaw, A.
Priest, A. N.
Gill, A.
Fryer, T.
Hong, Y. T.
Smith, R.
Backen, A.
Whitcher, B.
Jonson, A.
Richards, D.
Cookson, L.
Lee, W. M. F.
Dive, C.
Fife, K. M.
Jodrell, D. I.
Eisen, T.
机构：
[1] NIHR Cambridge Biomed Res Ctr, Cambridge, England
[2] Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England
[3] GlaxoSmithKline Clin Imaging Ctr, London, England
[4] GlaxoSmithKline, Cambridge, England
[5] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS155
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma.
    O'Dwyer, PJ
    Rosen, M
    Gallagher, M
    Schwartz, B
    Flaherty, KT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 193S - 193S
  • [2] Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma.
    Liu, Xiande
    Hoang, Anh
    Zhou, Lijun
    Kalra, Sarathi
    Yetil, Alper
    Sun, Mianen
    Ding, Zhiyong
    Tamboli, Pheroze
    Rao, Priya
    Karam, Jose A.
    Wood, Christopher G.
    Matin, Surena F.
    Zurita, Amado J.
    Bex, Axel
    Griffioen, Arjan W.
    Gao, Jianjun
    Sharma, Padmanee
    Tannir, Nizar M.
    Sircar, Kanishka
    Jonasch, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [3] Patients perspectives on adjuvant therapy in renal cell carcinoma.
    Battle, Dena
    Jonasch, Eric
    Hammers, Hans J.
    Derweesh, Ithaar
    George, Daniel J.
    Bex, Axel
    Ljungberg, Borje
    Staehler, Michael D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma
    Elaraj, DM
    White, DE
    Steinberg, SM
    Haworth, K
    Rosenberg, SA
    Yang, JC
    [J]. JOURNAL OF IMMUNOTHERAPY, 2004, 27 (04) : 259 - 264
  • [5] Chromosomal Imbalances Identify Pathways Associated with Resistance to Antiangiogenic Therapy in Clear Cell Renal Cell Carcinoma.
    Monzon, F. A.
    Alvarez, K.
    Peterson, L.
    Sircar, K.
    Tamboli, P.
    Jonasch, E.
    [J]. LABORATORY INVESTIGATION, 2011, 91 : 212A - 212A
  • [6] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF TUMOR SHRINKAGE BY AXITINIB IN PATIENTS WITH RENAL CELL CARCINOMA.
    Chen, Y.
    Houk, B. A.
    Ruiz, A.
    Bair, A. A.
    Pithavala, Y. K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S31 - S31
  • [7] Antiangiogenic treatment in patients with renal cell carcinoma
    Zolnierek, Jakub
    Szczylik, Cezary
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2009, 5 : A32 - A38
  • [8] Antiangiogenic therapy in renal cell carcinoma: a plethora of choices
    Sternberg, Cora N.
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (08): : 422 - 423
  • [9] Antiangiogenic therapy in renal cell carcinoma: a plethora of choices
    Cora N Sternberg
    [J]. Nature Clinical Practice Urology, 2008, 5 : 422 - 423
  • [10] Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma.
    Monzon, F. A.
    Alvarez, K.
    Amato, R. J.
    Peterson, L.
    Shen, S. S.
    Hernandez-McClain, J.
    Sircar, K.
    Tamboli, P.
    Tannir, N. M.
    Jonasch, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345